Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8852W HIGH $2.73
Volume
39.47 K
Value Traded
66.33 K
Short % Float
0.69%
+12.9%Week
+16.67%1 Month
-2.78%3 Month
-0.71%6 Month
-99.44%5 Year
-99.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
13.80 M
EPS (TTM)
-1.89
P/E Ratio
-
Ent. Value
-4.15 M
Total Shares
9.86 M
Float Shares
9.13 M
Insiders
7.35%
Institutions
38.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
INAB Catalyst Timeline
Dated clinical, regulatory and corporate events for IN8bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for IN8bio, Inc.
423Total events
10Upcoming
37Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
IN8bio to present fireside chat at H.C. Wainwright 28th Annual Global Investment Conference
●Management ChangeCorporate
IN8bio appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
●IND Enabling CompleteINB-619Preclinical
INB-619 advancing into IND-enabling studies
oncology and autoimmune diseasessource ↗
▲PublicationPresentation
Phase 1 INB-200 data published in Journal of Clinical Oncology
newly diagnosed glioblastomasource ↗
▲Oral PresentationPresentation
Translational data presented at ISCT and ASGCT Annual Meetings
newly diagnosed glioblastomasource ↗
●PublicationPresentation
CSO co-authored review in Nature Communications on gamma delta T cell engineering
◆FDA Feedback ReceivedFDA Meeting
FDA discussions regarding regulatory pathways for DeltEx DRI GBM program expected
newly diagnosed glioblastomasource ↗
▲PublicationINB-200Presentation
Publication of Phase 1 trial results of INB-200 in The Journal of Clinical Oncology
newly diagnosed glioblastomasource ↗
●PublicationPresentation
Publication in Nature Communications: Harnessing γδ T cells through engineering and combination therapies
▲Oral PresentationPresentation
Updated data presented at ASCO 2026 showing mOS >19.5 months
newly diagnosed glioblastomasource ↗
◆Poster PresentationINB-200Presentation
Poster at ASCO 2026: INB-200 Phase I study in newly diagnosed GBM
Glioblastoma multiforme (GBM)source ↗
◆Oral PresentationPresentation
Presented translational data at ISCT 2026 and ASGCT 2026
glioblastomasource ↗
◆Oral PresentationPresentation
Oral presentation at ASGCT 2026: Challenging the Glioblastoma Status Quo: Could γδ T Cells Shift the Balance?
Glioblastomasource ↗
◆Poster PresentationPresentation
Poster at ISCT 2026: Unraveling Complexity: The Impact, Interactions and Outcomes of a γδ T Cell Therapy in Glioblastoma
Glioblastomasource ↗
◆Oral PresentationPresentation
IO360° Conference: IN8bio’s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors & Results from Phase 1/2 Study in Newly Diagnosed GBM
glioblastomasource ↗
●Management ChangeCorporate
Promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer
▲Full ResultsINB-200Clinical Data
Updated data reported from Phase 1 INB-200 trial in newly diagnosed GBM
newly diagnosed glioblastomasource ↗
▲Full ResultsINB-400Clinical Data
Updated data reported from Phase 2 INB-400 trial in newly diagnosed GBM
newly diagnosed glioblastomasource ↗
▲Topline ReadoutClinical Data
Updated mPFS and mOS data as of December 31, 2025
newly diagnosed glioblastomasource ↗
▲Trial InitiationINB-100Trial
Addition of The Ohio State University as new clinical site for INB-100 Phase 1 trial
leukemias undergoing haploidentical stem cell transplantationsource ↗
◆Oral PresentationINB-619Presentation
Preclinical data for INB-619 presented at ACR 2025
systemic lupus erythematosussource ↗
◆Preclinical PoCINB-619Preclinical
Additional preclinical data from INB-619 T cell engager program in 4Q25
cancer and autoimmune diseasessource ↗
◆Oral PresentationINB-619Presentation
Presented new preclinical data on INB-619 at ACR Convergence 2025
autoimmune diseasessource ↗
▲Enrollment UpdateINB-100Trial
Expanded INB-100 clinical trial to multiple sites to accelerate enrollment
acute myeloid leukemiasource ↗
◆Topline ReadoutINB-100Clinical Data
Expect to present updated clinical data in second half of 2025
high-risk leukemias including AMLsource ↗
▲Long Term DataINB-200Clinical Data
Patient 009 achieves 4-year remission in Phase 1 trial of INB-200 for GBM
newly-diagnosed glioblastomasource ↗
▲Full ResultsINB-200Clinical Data
Long-term clinical data from Phase 1 trial of INB-200 announced
newly diagnosed glioblastoma multiforme (GBM)source ↗
▲Oral PresentationINB-200Presentation
Oral presentation at ASCO 2025 showing mPFS of 16.1 months in GBM patients receiving multiple doses of INB-200
glioblastomasource ↗
◆Oral PresentationINB-200Presentation
INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ)
newly diagnosed glioblastoma multiforme (GBM)source ↗
◆Oral PresentationPresentation
Decoding the Molecular Signature of Expanded Gamma-delta T Cell Products; TCR and Immune Gene Expression from Allogeneic derived Products
◆Poster PresentationINB-600Presentation
Poster at ASGCT 2025 on INB-600 TCE platform
Autoimmune diseases (Lupus)source ↗
◆Poster PresentationINB-600Presentation
INB-600: A Novel T Cell Engager Platform Specific for gamma-delta (γδ) T cells
▲Poster PresentationINB-619Presentation
Preclinical data for INB-619 presented at ASGCT 2025
Systemic Lupus Erythematosussource ↗
▲Oral PresentationPresentation
Oral presentation at ISCT 2025 on proprietary γδ T cell manufacturing
◆Enrollment UpdateINB-100Trial
INB-100 trial continues to enroll expansion cohort at RP2D
acute myeloid leukemiasource ↗
◆Oral PresentationPresentation
From Donor to Therapy: How Robust Manufacturing Shapes the TCR Repertoire and Cytotoxic Power of Donor-Derived Allogeneic ex vivo Expanded and Activated γδ T Cell Products
Past FDA Catalysts and PDUFA Decisions
How INAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-12 | DeltEx Drug Resistant Immunotherapy (DRI) | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 82%
Micro Cap(rank 537 of 655)
Percentile Rank
IN8bio, Inc. faces pipeline headwinds (25/100), with $47M risk-adjusted pipeline value, led by INB-400 in Glioblastoma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INB-400 Monoclonal antibodyNCT05664243 | Glioblastoma | Phase 1 | ACTIVE NOT_RECRUITING | 4 | Dec 1, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every INAB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| INB-200 | newly diagnosed glioblastoma | Phase 1 | 2026-07-09 | m PFS repeat dose: 16.1 months; m PFS all patients: 9.9 months; SOC m PFS: 6.9 months; OS repeat dose: 19.5 months; SOC m OS: 14.6 monthsRead More | IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed GlioblastomaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FAIRBAIRN EMILYDirector | Disposition | -724,637 | $0.00 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in INAB for Q2 2026. | ||||
INAB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INAB ranks across every disease it competes in
Competitive Position is a premium feature
See how INAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINAB News
INABIN8bio to Present at Sidoti Small-Cap Virtual Conference
IN8bio, Inc. announced that CEO William Ho will present at the Sidoti Small-Cap Virtual Conference on September 24, 2026. The presentation will highlight the company's unique gamma-delta T cell platform and its lead program, INB-619, along with other clinical-stage initiatives. Investors can participate in one-on-one meetings during the event.
Read more →INABIN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
IN8bio, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. CEO William Ho will lead a fireside chat and the management team will meet with investors. The event will be webcasted for broader access.
Read more →INAB▼ -5.3%on this newsshared move
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
IN8bio has appointed Dr. Oxana Polyakova as Senior Vice President of Research & Development. Dr. Polyakova, an expert in gamma-delta T cell biology, brings extensive experience from her previous roles in various biotech companies. Her leadership is expected to enhance IN8bio's T cell engager programs and advance their therapeutic pipeline.
Read more →INAB▲ +7.6%on this news
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio, Inc. has granted a nonqualified stock option for 4,000 shares to a new employee as part of its 2026 Inducement Plan. This grant, approved by the Compensation Committee, is in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years. IN8bio focuses on developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases.
Read more →INABIN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
IN8bio reported strong second quarter results, highlighting advancements in its gamma-delta T cell engager platform and promising clinical data for its DeltEx DRI in glioblastoma patients. The median overall survival for treated patients exceeded 19.5 months, with no significant toxicities observed. The company aims to continue its progress with upcoming preclinical data and regulatory discussions.
Read more →INABIN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
IN8bio announced the publication of clinical results demonstrating that its DeltEx DRI therapy significantly improves progression-free survival in newly diagnosed glioblastoma patients. The Phase 1 trial showed a median progression-free survival of 16.1 months for repeat-dose patients, more than double the standard of care. The therapy was well tolerated with no dose-limiting toxicities reported, highlighting its potential as a new treatment option for this aggressive cancer.
Read more →INABIN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
IN8bio, a clinical-stage biopharmaceutical company, has announced the publication of a review article in Nature Communications, focusing on advancements in gamma-delta T cell engineering and combination therapies for cancer. The publication, authored by leading oncologists, outlines innovative strategies that could enhance anti-tumor efficacy, especially in solid tumors. In particular, the unique properties of gamma-delta T cells and their potential to improve immunotherapy approaches are underscored.
Read more →INAB▼ -7.5%on this news· ran to -18% by day 3shared move
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
IN8bio presented updated clinical data for its DeltEx DRI at the ASCO 2026 conference, showing a median overall survival exceeding 19.5 months and a median progression-free survival of 13.0 months among patients with newly diagnosed glioblastoma. This data indicates a significant advancement over the standard-of-care, which has not changed in over 20 years. The therapy was well tolerated with no notable adverse effects, suggesting a positive outlook for patients facing this aggressive cancer. These findings underscore the potential of gamma-delta T cell therapy in transforming glioblastoma treatment outcomes.
Read more →INABIN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
IN8bio has presented new translational data highlighting the effectiveness of its DeltEx Drug Resistant Immunotherapy (DRI) in glioblastoma at major scientific forums. The findings suggest that repeated dosing of genetically modified gamma-delta T cells can preserve immune function and improve survival outcomes in patients. Data indicates a significant increase in intratumoral CD8+ T cell density, alongside reduced immune exhaustion markers, supporting the therapy's potential in reshaping the tumor microenvironment. The research lays the groundwork for future biomarker discovery and treatment optimization.
Read more →INABIN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
IN8bio reported its financial results for Q1 2026, highlighting advancements in its gamma-delta T cell therapies. The company has shown promising data for glioblastoma treatments and plans to engage with the FDA regarding regulatory pathways. Upcoming milestones include presentations at major conferences and further updates at their R&D Day in May.
Read more →INABIN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
IN8bio, a clinical-stage biopharmaceutical company, is set to present new clinical data and showcase its gamma-delta T cell programs at several upcoming medical conferences. Notably, they will hold an R&D Day on May 21, 2026, where they will highlight their novel T cell engager platform and its applications for cancer therapy. Key presentations will also occur at the ASCO Annual Meeting, focusing on the clinical progress of their gamma-delta T cell therapies for glioblastoma and other indications.
Read more →INABIN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
IN8bio reported its financial results for Q4 and full-year 2025, highlighting advancements in its gamma-delta T cell therapy programs, particularly for glioblastoma. The company announced a $40.2 million private placement to strengthen its financial position. Updated clinical data showed improved survival outcomes for patients treated with their therapies, indicating progress despite the aggressive nature of the disease.
Read more →INABIN8bio to Present at TD Cowen 46th Annual Health Care Conference
IN8bio, a clinical-stage biopharmaceutical company, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO William Ho will discuss the company's recent achievements and upcoming milestones. The conference will also feature one-on-one investor meetings and will take place in Boston from March 2-4, 2026.
Read more →INABIN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
IN8bio has promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer. Dr. Rochlin, who has been with the company since 2020, will oversee operations as IN8bio advances its clinical pipeline. She has played a key role in developing the company's T cell engager platform and has extensive experience in biotechnology. Her promotion is expected to strengthen the organization further.
Read more →INABIN8bio to Present at Upcoming Investor and Scientific Conferences in February
IN8bio, Inc. announced its participation in two upcoming conferences in February 2026. CEO William Ho will present at the Noble Emerging Growth Virtual Equity Conference and the IO360° Conference, where he will discuss the company's unique DeltEx Drug Resistant Immunotherapy approach and results from a Phase 1/2 study in glioblastoma. Additional details will be available on their website.
Read more →INAB▼ -7.2%on this news
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
IN8bio, Inc. has reported updated clinical data from its INB-200 and INB-400 trials for newly diagnosed glioblastoma, highlighting significant survival improvements with its DeltEx Drug-Resistant Immunotherapy gamma-delta T cells. The median progression-free survival has doubled compared to the standard-of-care, with many patients remaining progression-free for several years. Overall survival rates continue to improve, and treatment is well-tolerated with no severe adverse events. These results showcase the potential of DeltEx DRI to enhance outcomes for glioblastoma patients.
Read more →INAB▲ +28.1%on this news· ran to +84% by day 3
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
IN8bio has announced a private placement to raise up to $40.2 million, with an initial closing of $20.1 million. The funds will support the development of INB-619, a novel gamma-delta T cell engager, and extend the company's financial runway into 2027. The financing includes participation from various institutional investors and aims to facilitate IND enabling studies and FDA interactions.
Read more →INAB▼ -6.6%on this news
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
IN8bio, Inc. reported its financial results for Q3 2025, highlighting significant advancements in its gamma-delta T cell therapies. The company presented promising preclinical data on INB-619 and expanded its INB-100 clinical trial to multiple sites. CEO William Ho emphasized the potential of their DeltEx platform and the goal of redefining immune modulation for better patient outcomes.
Read more →About IN8bio, Inc.
HeadquartersEMPIRE STATE BUILDING, NEW YORK, NY, 10118
BIOPHARMAWATCH ELITE PLUS
Trade the next INAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime